Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.

Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011 Mar 15; 71(6):2298-307.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.